Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
2seventy bio, Inc. - Common Stock
(NQ:
TSVT
)
4.760
+0.060 (+1.28%)
Streaming Delayed Price
Updated: 3:20 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 2seventy bio, Inc. - Common Stock
< Previous
1
2
3
Next >
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
August 07, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
August 05, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
June 26, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
May 23, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
May 08, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
May 03, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
April 01, 2024
From
2seventy bio, Inc.
Via
Business Wire
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
April 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
March 20, 2024
From
2seventy bio, Inc.
Via
Business Wire
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
March 15, 2024
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
March 05, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
March 01, 2024
From
2seventy bio, Inc.
Via
Business Wire
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
February 27, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
2seventy bio to Participate in Upcoming Investor Conferences
February 05, 2024
From
2seventy bio, Inc.
Via
Business Wire
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
February 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio Announces New Strategic Path Forward
January 30, 2024
From
2seventy bio, Inc.
Via
Business Wire
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
December 11, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
December 06, 2023
From
2seventy bio, Inc.
Via
Business Wire
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
November 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
November 14, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023
November 10, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway
September 12, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies
September 12, 2023
From
2seventy bio
Via
Business Wire
2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference
September 06, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
August 14, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023
August 08, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare Conference
August 01, 2023
From
2seventy bio
Via
Business Wire
2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia
June 14, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Participate in Upcoming Investor Conference
June 07, 2023
From
2seventy bio, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.